New Hope for Late-stage Thyroid Cancer Patients
The Food and Drug Administration has approved the first new drug to treat advanced thyroid cancer in 40 years. Now patients have new hope for more time — and more treatment possibilities down the road.
In its priority review program, which fast-tracks review of drugs for serious conditions, the FDA approved use of the cancer drug sorafenib for patients with a late-stage (metastatic) differentiated thyroid cancer that no longer responds to radioactive iodine treatment.
The development opens up, too, the possibilities of new treatments of this type of advanced thyroid cancer with cancer drugs. Thyroid cancer is usually treated by endocrinologists because medical oncology had no effective treatment for those patients who became resistant to radioactive iodine.
Sorafenib (Nexavar®) is also used to treat liver and kidney cancer. Learn more.